Physician profile
Kent Vandevrede
NPI 1194163279
$597.88
in general payments reported to CMS, 2019-2025
15 companies · $39.92 in 2025
The $39.92 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $63.12 · 2021: $80.23 · 2022: $71.97 · 2023: $62.34 · 2024: $53.84 · 2025: $39.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $156.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $127.22 | 2020-2025 | Camzyos |
| Abbvie INC. | $101.78 | 2019-2023 | Teflaro |
| Novo Nordisk INC | $92.41 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $47.19 | 2019-2022 | |
| Pfizer INC. | $40.39 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $30.95 | 2019 | |
| Shire North American Group INC | $24.52 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.97 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $19.89 | 2019 | |
| Boston Scientific Corporation | $18.51 | 2023 | Watchman Access System |
| Allergan, INC. | $16.26 | 2020 | |
| Astellas Pharma US INC | $15.40 | 2019 | |
| Mylan Specialty L.P. | $14.04 | 2021 | |
| Sunovion Pharmaceuticals INC. | $13.79 | 2019 | |
| Merck Sharp & Dohme LLC | $13.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Vandevrede listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.